To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B
Authors:
Open Access
- 1 October 2013
- journal article
- research article
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 17 (5) , 283-287
Abstract
Aim : The aim of this study was to evaluate the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury (AKI) associated with the parenteral polymyxin B in patients with the multidrug resistance (MDR) gram −ve infections in a tertiary Intensive care unit (ICU). Materials and Methods : A retrospective cohort study (March 2010-October 2011) was conducted in Medical ICU of a 23 bedded tertiary care hospital in Northern India. Results : Out of 71 ICU patients who were administered polymyxin B, only 32 (M:F = 1:0.8) met the inclusion criteria. Patients with concurrent administration of nephrotoxic drugs were excluded from the study. Mean age of patients was 48.53 ± 13.90 years ranging from 16 years to 68 years. 6 out of 32 (18.7%) patients progressed to AKI, whereas renal functions remained normal in 26 (81.2%) patients. No statistically significant difference was observed in mortality between AKI and non AKI patients at the end of therapy (33.3% vs. 26.9%, P value 0.756). Older age (62.33 ± 11.90 vs. 45.34 ± 2.45, P value 0.005) was found to be an independent risk factor for causing nephrotoxicity. Conclusion : In the present scenario of rising infections with MDR gram −ve micro-organisms, this pilot study suggests that polymyxin B can be used effectively and safely in patients not receiving other nephrotoxic drugs, with cautious administration in older patients as they are more vulnerable to nephrotoxicity caused by polymyxin B.Keywords
This publication has 25 references indexed in Scilit:
- Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09)Journal of Antimicrobial Chemotherapy, 2011
- New treatment options against gram-negative organismsCritical Care, 2011
- Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemiaJournal of Antimicrobial Chemotherapy, 2010
- Safety and efficacy of polymyxin B in multidrug resistant gram-negative severe sepsis and septic shockIndian Journal of Critical Care Medicine, 2008
- Polymyxins RevisitedClinical Microbiology Reviews, 2008
- Device-associated nosocomial infection rates in intensive care units of seven Indian cities. Findings of the International Nosocomial Infection Control Consortium (INICC)Journal of Hospital Infection, 2007
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005
- APACHE IICritical Care Medicine, 1985
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976